What's Happening?
Medtronic has secured FDA approval for the Altaviva device, a minimally invasive implantable tibial neuromodulation therapy for urge urinary incontinence. The device is inserted near the ankle and helps restore communication between the bladder and the brain to regulate bladder control. This approval expands treatment options for millions of people affected by bladder control issues.
Why It's Important?
The Altaviva device offers a new, less invasive treatment option for urge urinary incontinence, potentially improving patient outcomes and quality of life. With a long battery lifespan and MRI compatibility, the device provides convenience and peace of mind for patients. Medtronic's approval underscores its commitment to innovation in neuromodulation therapies, enhancing its position as a leader in the field.
What's Next?
Medtronic plans to host an investor call to discuss the impact of the Altaviva device on the treatment landscape for urge urinary incontinence. As the device becomes more widely available, Medtronic may see increased market share and further development of its neuromodulation portfolio. The company is expected to continue pushing the boundaries of innovation in bladder control therapies.
